RFA-ES-22-006: New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $1.8 million to small businesses. Applications closed on November 8, 2022.
From the official notice on Grants.gov, last changed June 30, 2022. Checked November 7, 2026.
- Award ceiling$1.8 million
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR43 / R44
- Clinical trialsNot allowed
- Funded byNIEHS
- Median yearly award$558,601
- Typical project length2 years
- R43, Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Other open R43 notices.
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Projects funded under RFA-ES-22-006 were run by National Institute of Environmental Health Sciences (NIEHS, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-ES-22-006 in the NIH Guide.
Key dates
| Posted | June 30, 2022 |
|---|---|
| Deadline | November 8, 2022 |
| Archived by Grants.gov | December 14, 2022 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $558,601; it allows up to $1.8 million per award.
- Most of the program's money (81% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources and approaches, including panels of cells or model organisms, that reflect the variability in human populations in chemical toxicity testing . Current toxicology testing is often limited to studies conducted in a small number of laboratory rodent strains, which can fail to identify clinically relevant toxicity if the conventional rodent strain is particularly resistant to the toxic effects of the test compound. Cost-effective screening systems with appropriate throughput are needed to better capture this variability in responses to chemical exposure in the population based on individual genetic susceptibility.
Funded under RFA-ES-22-006 so far
NIH funded 3 projects under RFA-ES-22-006 in fiscal 2023 to 2024, at 3 institutions. The median yearly award was $558,601.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| The Next-Generation Developmental and Reproductive Toxicology (DART) Assay using High-Content Analysis of Genetically Diverse C. elegans Populations | Vivoverse, LLC | 2024 | $841,749 |
| Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors | Litron Laboratories, LTD. | 2023 | $230,278 |
| A liver-on-chip platform to evaluate panels of clinically relevant gene variants for screening of xenobiotic compounds | Nortis, Inc. | 2023 | $275,453 |
Who has won Environmental Health grants before
From fiscal 2021 to 2025, Environmental Health (93.113) awarded $2.1 billion across 1,980 grant awards, an average of $1.1 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | 49 | $87.7 million |
| The Trustees of Columbia University in the City of New York | New York | 69 | $78.7 million |
| University of North Carolina at Chapel Hill | North Carolina | 59 | $71.5 million |
| Emory University | Georgia | 57 | $67.2 million |
| University of Southern California | California | 40 | $58.9 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-ES-22-006 still open?
No. It closed on November 8, 2022.
Who can apply for New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for New Approaches for Incorporating Genetic Diversity into Toxicity Testing (R43/R44 Clinical Trial Not Allowed)?
Closed November 8, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.8 million each.
Who has been funded under RFA-ES-22-006?
NIH RePORTER lists 3 projects funded under RFA-ES-22-006 in fiscal 2023 to 2024, at 3 institutions. The most were at Vivoverse, LLC, Litron Laboratories, LTD., Nortis, Inc.
Who has won Environmental Health grants before?
The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)